Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China

doi:10.19982/j.issn.1000-6621.20250042

Abstract

Abstract:

Timely identification of active tuberculosis (TB) patients and individuals with latent tuberculosis infection (LTBI), followed by targeted treatment, constitutes a critical strategy for TB epidemic control. Digital adherence technology (DAT) utilizes digital tools to assist healthcare providers in monitoring and promoting medication compliance among TB patients and those undergoing preventive treatment, thereby enhancing therapeutic adherence. This guideline systematically summarized the characteristics and practical evidence of DAT currently implemented in China’s TB prevention and control efforts, including video-observed therapy, electronic medication monitors, mobile applications, and SMS reminders. It further proposes recommendations for the application of DAT in supporting anti-TB treatment and TB preventive therapy, aiming to offer evidence-based guidance for the optimization and refinement of TB medication management strategies using DAT across various regions.

Key words: Tuberculosis, Self administration, Disease management, Digital adherence technology, Consensus development conferences as topic

CLC Number:

Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China[J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397. doi: 10.19982/j.issn.1000-6621.20250042

Figures/Tables 2

References 85

[1]	胡鑫洋, 高静韬. 世界卫生组织《2024年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5(6): 500-504. doi:10.19983/j.issn.2096-8493.2024164.
[2]	李鹏, 李云红, 雷丽梅, 等. 肺结核患者服药依从性的研究进展. 中国医药科学, 2023, 13(7): 58-62. doi:10.3969/j.issn.2095-0616.2023.07.016.
[3]	Smith MK, Henderson-Andrade N. Facing the health worker crisis in developing countries: a call for global solidarity. Bull World Health Organ, 2006, 84(6):426. doi:10.2471/blt.06.031757.
[4]	Hu D, Liu X, Chen J, et al. Direct observation and adherence to tuberculosis treatment in Chongqing, China: a descriptive study. Health Policy Plan, 2008, 23(1):43-55. doi:10.1093/heapol/czm038.
[5]	汪依帆, 严非, 吴来娃. 上海市肺结核病患者对督导访视的满意度及需求分析. 中国初级卫生保健, 2013, 27(8): 73-75. doi:10.3969/j.issn.1001-568X.2013.08.0030.
[6]	McQuaid CF, Foster N, Quaife M, et al. Digital adherence technology for TB: focus on livelihoods as well as lives. Int J Tuberc Lung Dis, 2021, 25(5):416-417. doi:10.5588/ijtld.21.0070. pmid: 33977914
[7]	Liu X, Lewis JJ, Zhang H, et al. Effectiveness of Electronic Reminders to Improve Medication Adherence in Tuberculosis Patients: A Cluster-Randomised Trial. PLoS Med, 2015, 12(9):e1001876. doi:10.1371/journal.pmed.1001876.
[8]	World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: World Health Organization, 2017.
[9]	The Global Fund. Fighting pandemics and building a healthier and more equitable world: global fund strategy (2023—2028). Geneva: The Global Fund, 2021.
[10]	中华人民共和国国家疾病预防控制局, 中华人民共和国国家卫生健康委员会, 中华人民共和国国家发展和改革委员会, 等. 关于印发《全国结核病防治规划(2024—2030年)》的通知. 国疾控传防发〔2024〕19号. 2024-11-28.
[11]	World Health Organization. WHO handbook for guideline development. 2nd ed. Geneva: World Health Organization, 2014.
[12]	Chen Y, Yang K, Marušic A, et al. A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med, 2017, 166(2):128-132. doi:10.7326/M16-1565. pmid: 27893062
[13]	Brouwers MC, Kho ME, Browman GP, et al. AGREE Ⅱ: advancing guideline development, reporting, and evaluation in health care. Prev Med, 2010, 51(5): 421-424. doi:10.1016/j.ypmed.2010.08.005. pmid: 20728466
[14]	蒋朱明, 詹思延, 贾晓巍, 等. 制订/修订《临床诊疗指南》的基本方法及程序. 中华医学杂志, 2016, 96(4): 250-253. doi:10.3760/cma.j.issn.0376-2491.2016.04.004.
[15]	陈耀龙, 杨克虎, 王小钦, 等. 中国制订/修订临床诊疗指南的指导原则(2022版). 中华医学杂志, 2022, 102(10): 697-703. doi:10.3760/cma.j.cn112137-20211228-02911.
[16]	World Health Organization. Handbook for the use of digital technologies to support tuberculosis medication adherence. Geneva: World Health Organization, 2017.
[17]	中国防痨协会. T/CHATA 012—2021 电子药盒辅助结核病患者规范服药的管理指南. 2021-05-12.
[18]	中国防痨协会. T/CHATA 019—2022 肺结核患者管理移动应用程序的功能及应用规范. 2022-02-24.
[19]	Subbaraman R, de Mondesert L, Musiimenta A, et al. Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities. BMJ Glob Health, 2018, 3(5): e001018. doi:10.1136/bmjgh-2018-001018.
[20]	Velen K, Nguyen TA, Pham CD, et al. The effect of medication event reminder monitoring on treatment adherence of TB patients. Int J Tuberc Lung Dis, 2023, 27(4):322-328. doi:10.5588/ijtld.22.0500. pmid: 37035979
[21]	Burzynski J, Mangan JM, Lam CK, et al. In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence: A Randomized Noninferiority Trial. JAMA Netw Open, 2022, 5(1):e2144210. doi:10.1001/jamanetworkopen.2021.44210.
[22]	Ngwatu BK, Nsengiyumva NP, Oxlade O, et al. The impact of digital health technologies on tuberculosis treatment: a systematic review. Eur Respir J, 2018, 51(1):1701596. doi:10.1183/13993003.01596-2017.
[23]	Goscé L, Tadesse AW, Foster N, et al. Modelling the epidemiological and economic impact of digital adherence technologies with differentiated care for tuberculosis treatment in Ethiopia. BMJ Glob Health, 2024, 9(12):e016997. doi:10.1136/bmjgh-2024-016997.
[24]	Ridho A, Alfian SD, van Boven JFM, et al. Digital Health Technologies to Improve Medication Adherence and Treatment Outcomes in Patients With Tuberculosis: Systematic Review of Randomized Controlled Trials. J Med Internet Res, 2022, 24(2):e33062. doi:10.2196/33062.
[25]	de Groot LM, Straetemans M, Maraba N, et al. Time Trend Analysis of Tuberculosis Treatment While Using Digital Adherence Technologies-An Individual Patient Data Meta-Analysis of Eleven Projects across Ten High Tuberculosis-Burden Countries. Trop Med Infect Dis, 2022, 7(5):65. doi:10.3390/tropicalmed7050065.
[26]	Alipanah N, Jarlsberg L, Miller C, et al. Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies. PLoS Med, 2018, 15(7):e1002595. doi:10.1371/journal.pmed.1002595.
[27]	Liu X, Thompson J, Dong H, et al. Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomised superiority trial. Lancet Glob Health, 2023, 11(5): e693-e703. doi:10.1016/S2214-109X(23)00068-2. pmid: 37061308
[28]	Wei X, Hicks JP, Zhang Z, et al. Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial. Lancet, 2024, 403(10430):913-923. doi:10.1016/S0140-6736(23)02270-5. pmid: 38309280
[29]	Wu Z, Lu L, Li Y, et al. Effect of mobile health reminders on tuberculosis treatment outcomes in Shanghai, China: A prospective cohort study. Front Public Health, 2023, 11:923319. doi:10.3389/fpubh.2023.923319.
[30]	Guo X, Yang Y, Takiff HE, et al. A Comprehensive App That Improves Tuberculosis Treatment Management Through Video-Observed Therapy: Usability Study. JMIR Mhealth Uhealth, 2020, 8(7):e17658. doi:10.2196/17658.
[31]	Zhang M, Wang G, Najmi H, et al. Digitizing tuberculosis treatment monitoring in Wuhan city, China, 2020—2021: Impact on medication adherence. Front Public Health, 2023, 11:1033532. doi:10.3389/fpubh.2023.1033532.
[32]	Zhou L, Zhou Y, Ding Y, et al. Digital tool assessment for the community management of patients with pulmonary tuberculosis in Yiwu city, China: evidence from real world data in 2020. Front Public Health, 2024, 11:1320904. doi:10.3389/fpubh.2023.1320904.
[33]	秦楠, 宁晨曦, 张祖荣, 等. 结核病患者手机应用程序督导服药的应用及其影响因素. 中国卫生资源, 2023, 26(4): 358-362, 369. doi:10.13688/j.cnki.chr.2023.230133.
[34]	Wang N, Zhang H, Zhou Y, et al. Using electronic medication monitoring to guide differential management of tuberculosis patients at the community level in China. BMC Infect Dis, 2019, 19(1):844. doi:10.1186/s12879-019-4521-2. pmid: 31615433
[35]	Li X, Pang X, Zhang F. Evaluation of Mobile Application for the Management of Tuberculosis Patients in Tianjin During 2019—2020. Patient Prefer Adherence, 2022, 16:321-329. doi:10.2147/PPA.S321289.
[36]	Guo G, Zheng Y, Ma X, et al. eDOTS: Improving the Treatment of Pulmonary Tuberculosis in Xinjiang, China. Infect Drug Resist, 2023, 16:7497-7505. doi:10.2147/IDR.S438962. pmid: 38089961
[37]	Mangan JM, Woodruff RS, Winston CA, et al. Recommendations for Use of Video Directly Observed Therapy During Tuberculosis Treatment-United States, 2023. MMWR Morb Mortal Wkly Rep, 2023, 72(12):313-316. doi:10.15585/mmwr.mm7212a4.
[38]	Truong CB, Tanni KA, Qian J. Video-Observed Therapy Versus Directly Observed Therapy in Patients With Tuberculosis. Am J Prev Med, 2022, 62(3):450-458. doi:10.1016/j.amepre.2021.10.013.
[39]	Chen EC, Owaisi R, Goldschmidt L, et al. Patient perceptions of video directly observed therapy for tuberculosis: a systematic review. J Clin Tuberc Other Mycobact Dis, 2023, 35:100406. doi:10.1016/j.jctube.2023.100406.
[40]	Story A, Aldridge RW, Smith CM, et al. Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. Lancet, 2019, 393(10177):1216-1224. doi:10.1016/S0140-6736(18)32993-3. pmid: 30799062
[41]	Ravenscroft L, Kettle S, Persian R, et al. Video-observed therapy and medication adherence for tuberculosis patients: randomised controlled trial in Moldova. Eur Respir J, 2020, 56(2):2000493. doi:10.1183/13993003.00493-2020.
[42]	Guo P, Qiao W, Sun Y, et al. Telemedicine Technologies and Tuberculosis Management: A Randomized Controlled Trial. Telemed J E Health, 2020, 26(9):1150-1156. doi:10.1089/tmj.2019.0190. pmid: 31794684
[43]	张丹丹. 微信视频督导与可视健康教育对青少年肺结核患者服药依从性的影响. 世界临床医学, 2018, 12(2): 79,82.
[44]	Sinkou H, Hurevich H, Rusovich V, et al. Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience. Eur Respir J, 2017, 49(3):1602049. doi:10.1183/13993003.02049-2016.
[45]	Gassanov MA, Feldman LJ, Sebastian A, et al. The use of videophone for directly observed therapy for the treatment of tuberculosis. Can J Public Health, 2013, 104(3):e272. doi:10.17269/cjph.104.3869. pmid: 23823897
[46]	Story A, Garfein RS, Hayward A, et al. Monitoring Therapy Compliance of Tuberculosis Patients by using Video-Enabled Electronic Devices. Emerg Infect Dis, 2016, 22(3):538-540. doi:10.3201/eid2203.151620. pmid: 26891363
[47]	Chuck C, Robinson E, Macaraig M, et al. Enhancing management of tuberculosis treatment with video directly observed therapy in New York City. Int J Tuberc Lung Dis, 2016, 20(5):588-593. doi:10.5588/ijtld.15.0738. pmid: 27084810
[48]	Mukooza E, Schausberger B, Mmema N, et al. Understanding the role of video direct observed therapy for patients on an oral short-course regimen for multi-drug resistant tuberculosis: findings from a qualitative study in Eswatini. BMC Infect Dis, 2024, 24(1):829. doi:10.1186/s12879-024-09744-9. pmid: 39148081
[49]	Lam CK, McGinnis Pilote K, Haque A, et al. Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study. J Med Internet Res, 2018, 20(11):e287. doi:10.2196/jmir.9825.
[50]	Nguyen TA, Pham MT, Nguyen TL, et al. Video Directly Observed Therapy to support adherence with treatment for tuberculosis in Vietnam: A prospective cohort study. Int J Infect Dis, 2017, 65:85-89. doi:10.1016/j.ijid.2017.09.029. pmid: 29030137
[51]	Garfein RS, Liu L, Cepeda J, et al. Asynchronous Video Directly Observed Therapy to Monitor Short-Course Latent Tuberculosis Infection Treatment: Results of a Randomized Controlled Trial. Open Forum Infect Dis, 2024, 11(4):ofae180. doi:10.1093/ofid/ofae180.
[52]	Zary M, Mohamed MS, Kafie C, et al. The performance of digital technologies for measuring tuberculosis medication adherence: a systematic review. BMJ Glob Health, 2024, 9(7):e015633. doi:10.1136/bmjgh-2024-015633.
[53]	桓世彤, 陈嵘, 刘小秋, 等. 电子药盒取药记录监测肺结核患者服药行为的可行性评估. 中国防痨杂志, 2012, 34(7): 419-424.
[54]	Manyazewal T, Woldeamanuel Y, Getinet T, et al. Patient-reported usability and satisfaction with electronic medication event reminder and monitor device for tuberculosis: a multicentre, randomised controlled trial. EClinicalMedicine, 2023, 56:101820. doi:10.1016/j.eclinm.2022.101820.
[55]	Acosta J, Flores P, Alarcón M, et al. A randomised controlled trial to evaluate a medication monitoring system for TB treatment. Int J Tuberc Lung Dis, 2022, 26(1):44-49. doi:10.5588/ijtld.21.0373. pmid: 34969428
[56]	Moulding TS, Caymittes M. Managing medication compliance of tuberculosis patients in Haiti with medication monitors. Int J Tuberc Lung Dis, 2002, 6(4):313-319. pmid: 11936740
[57]	徐红, 陆峰. 运用电子药盒管理肺结核患者依从性分析. 江苏预防医学, 2013, 24(1): 51-52. doi:10.3969/j.issn.1006-9070.2013.01.023.
[58]	Bionghi N, Daftary A, Maharaj B, et al. Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa. BMC Infect Dis, 2018, 18(1):171. doi:10.1186/s12879-018-3080-2. pmid: 29642874
[59]	Menzies D, Dion MJ, Francis D, et al. In closely monitored patients, adherence in the first month predicts completion of therapy for latent tuberculosis infection. Int J Tuberc Lung Dis, 2005, 9(12):1343-1348. doi:10.1183/09031936.05.50028305. pmid: 16466056
[60]	Guzman K, Crowder R, Leddy A, et al. Acceptability and feasibility of digital adherence technologies for drug-susceptible tuberculosis treatment supervision: A meta-analysis of implementation feedback. PLOS Digit Health, 2023, 2(8):e0000322. doi:10.1371/journal.pdig.0000322.
[61]	张晗, 王丽霞, 魏玉石, 等. 数字化治疗依从性技术在肺结核患者服药管理中的应用效果评价. 中国防痨杂志, 2024, 46(2): 158-164. doi:10.19982/j.issn.1000-6621.20230283.
[62]	李勇, 路丽苹, 李瑾, 等. 肺结核患者对结核助手APP和电子药盒的使用意愿和效果分析. 结核与肺部疾病杂志, 2022, 3(1): 22-26. doi:10.19983/j.issn.2096-8493.20210110.
[63]	李雪, 姜世闻, 胡冬梅, 等. 电子药盒和手机微信APP的应用对肺结核患者服药依从性的效果评价. 中国防痨杂志, 2019, 41(9): 957-961. doi:10.3969/j.issn.1000-6621.2019.09.009.
[64]	Iribarren SJ, Milligan H, Chirico C, et al. Patient-centered mobile tuberculosis treatment support tools (TB-TSTs) to improve treatment adherence: A pilot randomized controlled trial exploring feasibility, acceptability and refinement needs. Lancet Reg Health Am, 2022, 13:100291. doi:10.1016/j.lana.2022.100291.
[65]	Haslinda N, Juni MH. Effectiveness of health education module delivered through whatsapp to enhance treatment adherence and successful outcome of tuberculosis in Seremban District, Negeri Sembilan, Malaysia. International Journal of Public Health and Clinical Sciences, 2019, 6(4). doi:10.32827/ijphcs.6.4.145.
[66]	薛晓, 张东彦, 艾萍, 等. 肺结核患者电子药盒和微信小程序使用情况分析. 中国防痨杂志, 2022, 44(7): 704-710. doi:10.19982/j.issn.1000-6621.20220102.
[67]	景睿, 曹艳民, 杨一军, 等. 电子药盒和手机微信APP对肺结核患者督导服药管理的应用研究. 结核病与肺部健康杂志, 2020, 1(2): 96-99. doi:10.3969/j.issn.2096-8493.2020.01.020.
[68]	史琰琰. 移动APP辅助肺结核患者管理系统满意度的定性研究. 健康教育与健康促进, 2021, 16(2): 194-196,220. doi:10.16117/j.cnki.31-1974/r.202102194.
[69]	Devi BR, Syed-Abdul S, Kumar A, et al. mHealth: An updated systematic review with a focus on HIV/AIDS and tuberculosis long term management using mobile phones. Comput Methods Programs Biomed, 2015, 122(2):257-265. doi:10.1016/j.cmpb.2015.08.003.
[70]	Morse RM, Myburgh H, Reubi D, et al. Opportunities for Mobile App-Based Adherence Support for Children With Tuberculosis in South Africa. JMIR Mhealth Uhealth, 2020, 8(11):e19154. doi:10.2196/19154.
[71]	中国互联网络信息中心. 第54次《中国互联网络发展状况统计报告》. 北京: 中国互联网络信息中心, 2024.
[72]	Mohammed S, Glennerster R, Khan AJ. Impact of a Daily SMS Medication Reminder System on Tuberculosis Treatment Outcomes: A Randomized Controlled Trial. PLoS One, 2016, 11(11):e0162944. doi:10.1371/journal.pone.0162944.
[73]	Bediang G, Stoll B, Elia N, et al. SMS reminders to improve adherence and cure of tuberculosis patients in Cameroon (TB-SMS Cameroon): a randomised controlled trial. BMC Public Health, 2018, 18(1):583. doi:10.1186/s12889-018-5502-x. pmid: 29720146
[74]	Nglazi MD, Bekker LG, Wood R, et al. Mobile phone text messaging for promoting adherence to anti-tuberculosis treatment: a systematic review protocol. Syst Rev, 2013, 2:6. doi:10.1186/2046-4053-2-6. pmid: 23324135
[75]	肖力, 黄亚菊. 短信随访对提高肺结核病人依从性和治愈率的研究. 护士进修杂志, 2014(24): 2289-2291.
[76]	梁大斌, 黄敏莹, 刘飞鹰, 等. 应用手机短信对肺结核患者治疗管理的效果研究. 现代预防医学, 2018, 45(5): 847-850,882.
[77]	Marcolino MS, Oliveira JAQ, D’Agostino M, et al. The Impact of mHealth Interventions: Systematic Review of Systematic Reviews. JMIR Mhealth Uhealth, 2018, 6(1):e23. doi:10.2196/mhealth.8873.
[78]	Albino S, Tabb KM, Requena D, et al. Perceptions and acceptability of short message services technology to improve treatment adherence amongst tuberculosis patients in Peru: a Focus Group Study. PLoS One, 2014, 9(5):e95770. doi:10.1371/journal.pone.0095770.
[79]	Iribarren SJ, Sward KA, Beck SL, et al. Qualitative evaluation of a text messaging intervention to support patients with active tuberculosis: implementation considerations. JMIR Mhealth Uhealth, 2015, 3(1):e21. doi:10.2196/mhealth.3971.
[80]	Garfein RS, Collins K, Muñoz F, et al. Feasibility of tuberculosis treatment monitoring by video directly observed therapy: a binational pilot study. Int J Tuberc Lung Dis, 2015, 19(9):1057-1064. doi:10.5588/ijtld.14.0923. pmid: 26260824
[81]	Holzman SB, Zenilman A, Shah M. Advancing Patient-Centered Care in Tuberculosis Management: A Mixed-Methods Appraisal of Video Directly Observed Therapy. Open Forum Infect Dis, 2018, 5(4):ofy046. doi:10.1093/ofid/ofy046.
[82]	Ni N, Wang N, Veronese V, et al. Current status and future prospects of TB digital treatment adherence technology use in China. Int J Tuberc Lung Dis, 2023, 27(6):438-443. doi:10.5588/ijtld.22.0540. pmid: 37231604
[83]	Liu X, Blaschke T, Thomas B, et al. Usability of a Medication Event Reminder Monitor System (MERM) by Providers and Patients to Improve Adherence in the Management of Tuberculosis. Int J Environ Res Public Health, 2017, 14(10):1115. doi:10.3390/ijerph14101115.
[84]	解艳涛, 杜建, 罗萍, 等. 2016年北京市通州区结核病患者移动督导管理应用程序使用情况初步报告. 中国防痨杂志, 2017, 39(7): 708-712. doi:10.3969/j.issn.1000-6621.2017.07.008.
[85]	Munro SA, Lewin SA, Smith HJ, et al. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med, 2007, 4(7):e238. doi:10.1371/journal.pmed.0040238. pmid: 17676945

分级	具体描述
证据质量
高(A)	非常有把握:确信真实的效果接近于估算的效果
中(B)	对观察值有中等把握:真实的效果可能接近于估算的效果,但也有很大差异的可能性
低(C)	对观察值的把握有限:真实的效果可能与估算的效果存在很大差异
极低(D)	对观察值几乎没把握:估算的效果很不确定,常常远离真相
推荐强度
强(1)	明确显示干预措施利大于弊或弊大于利
弱(2)	利弊不确定或无论质量高低的证据均显示利弊相当